CA3100020A1 - Mucus-penetrating peptides, delivery vehicles and methods of therapy - Google Patents
Mucus-penetrating peptides, delivery vehicles and methods of therapy Download PDFInfo
- Publication number
- CA3100020A1 CA3100020A1 CA3100020A CA3100020A CA3100020A1 CA 3100020 A1 CA3100020 A1 CA 3100020A1 CA 3100020 A CA3100020 A CA 3100020A CA 3100020 A CA3100020 A CA 3100020A CA 3100020 A1 CA3100020 A1 CA 3100020A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- mucus
- delivery vehicle
- composition
- penetrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 39
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 35
- 238000002560 therapeutic procedure Methods 0.000 title claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 38
- 235000001014 amino acid Nutrition 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 20
- 239000003981 vehicle Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 239000002105 nanoparticle Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 10
- 150000002632 lipids Chemical group 0.000 claims 9
- 238000012986 modification Methods 0.000 claims 9
- 230000004048 modification Effects 0.000 claims 9
- 235000018102 proteins Nutrition 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 7
- 235000018417 cysteine Nutrition 0.000 claims 6
- 108091005601 modified peptides Proteins 0.000 claims 6
- 238000002169 hydrotherapy Methods 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 201000001428 congenital diarrhea Diseases 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 150000001945 cysteines Chemical class 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 210000000110 microvilli Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 102100029790 Defensin-6 Human genes 0.000 claims 2
- 101000865479 Homo sapiens Defensin-6 Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000020603 familial colorectal cancer Diseases 0.000 claims 2
- 239000002479 lipoplex Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000000541 Defensins Human genes 0.000 claims 1
- 108010002069 Defensins Proteins 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671709P | 2018-05-15 | 2018-05-15 | |
| US62/671,709 | 2018-05-15 | ||
| PCT/US2019/032484 WO2019222400A2 (en) | 2018-05-15 | 2019-05-15 | Mucus-penetrating peptides, delivery vehicles and methods of therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3100020A1 true CA3100020A1 (en) | 2019-11-21 |
Family
ID=68540758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3100020A Pending CA3100020A1 (en) | 2018-05-15 | 2019-05-15 | Mucus-penetrating peptides, delivery vehicles and methods of therapy |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210177982A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3796892A2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2021523912A (cg-RX-API-DMAC10.html) |
| CN (1) | CN112367974A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019269590A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3100020A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019222400A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021119585A1 (en) * | 2019-12-13 | 2021-06-17 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| CA3168509A1 (en) * | 2020-02-19 | 2021-08-26 | Elias SAYOUR | Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
| WO2022260678A1 (en) * | 2021-06-11 | 2022-12-15 | Dnalite Therapeutics, Inc. | Compositions and methods for biological delivery vehicles |
| TW202241388A (zh) | 2020-12-14 | 2022-11-01 | 美商Ｄｎａ萊特治療公司 | 生物遞送系統 |
| US20220370624A1 (en) * | 2021-05-05 | 2022-11-24 | Arcturus Therapeutics, Inc. | Lipid compositions comprising peptide-lipid conjugates |
| EP4403549A4 (en) * | 2021-09-17 | 2026-06-10 | Univ Tohoku | COMPOSITE PLACE AND COMPOSITE COMPOSITE THE CONTAINER |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US176111A (en) | 1876-04-11 | Improvement in car-couplings | ||
| CA2716565C (en) * | 2008-02-28 | 2017-09-12 | Toray Industries, Inc. | Pharmaceutical composition for transnasal administration |
| WO2012109363A2 (en) * | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US9415020B2 (en) * | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| WO2013166408A1 (en) * | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR101669203B1 (ko) * | 2014-06-18 | 2016-10-25 | 한국과학기술연구원 | 신규 세포투과성 펩타이드 및 이의 용도 |
| WO2018013907A1 (en) * | 2016-07-15 | 2018-01-18 | Board Of Regents, The University Of Texas System | Mucus-penetrating peptides and screening assay |
| JP2019533645A (ja) * | 2016-09-16 | 2019-11-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ |
-
2019
- 2019-05-15 CN CN201980045452.2A patent/CN112367974A/zh active Pending
- 2019-05-15 WO PCT/US2019/032484 patent/WO2019222400A2/en not_active Ceased
- 2019-05-15 AU AU2019269590A patent/AU2019269590A1/en not_active Abandoned
- 2019-05-15 CA CA3100020A patent/CA3100020A1/en active Pending
- 2019-05-15 EP EP19804407.5A patent/EP3796892A2/en not_active Withdrawn
- 2019-05-15 JP JP2020564152A patent/JP2021523912A/ja not_active Withdrawn
-
2020
- 2020-11-13 US US17/098,053 patent/US20210177982A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3796892A2 (en) | 2021-03-31 |
| WO2019222400A2 (en) | 2019-11-21 |
| JP2021523912A (ja) | 2021-09-09 |
| AU2019269590A1 (en) | 2020-12-03 |
| US20210177982A1 (en) | 2021-06-17 |
| WO2019222400A3 (en) | 2020-02-13 |
| CN112367974A (zh) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020290516B2 (en) | Compositions and methods for biological delivery vehicles | |
| US20210177982A1 (en) | Mucus-penetrating peptides, delivery vehicles and methods of therapy | |
| Mollé et al. | Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery | |
| US20120258104A1 (en) | Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes | |
| US20230023615A1 (en) | Compositions and methods for biological delivery vehicles | |
| US20190351071A1 (en) | Structures and methods for gene therapy | |
| JP6141517B2 (ja) | 脂肪細胞標的非ウイルス性遺伝子伝達体 | |
| Zhao et al. | Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics | |
| Alexander-Bryant et al. | Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo | |
| WO2022260678A1 (en) | Compositions and methods for biological delivery vehicles | |
| JP2019533645A (ja) | 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ | |
| US9976142B2 (en) | Targeting molecule and a use thereof | |
| CA3205059A1 (en) | Biological delivery systems | |
| Geng et al. | Emerging landscape of cell-penetrating peptide-mediated organelle restoration and replacement | |
| Hall et al. | Peptide/lipid-associated nucleic acids (PLANAs) as a multicomponent siRNA delivery system | |
| US12036282B2 (en) | Liposomal system for drug delivery | |
| Fu et al. | Virus-inspired lipopeptide-derived nucleic acid delivery to cartilage for osteoarthritis therapy | |
| US11890352B2 (en) | Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer | |
| CN117337330A (zh) | TMEM173 saRNA组合物和使用方法 |